newsCD19 CAR-T agents to boost blood cancer market8 February 2023 | By Catherine Eckford (European Pharmaceutical Review)GlobalData says CD19 CAR-T agents are expected to treat over 13,000 blood cancer patients annually by 2031, driving sales of Breyanzi and Yescarta.
newsCHMP meeting highlights – January 202330 January 2023 | By Catherine Eckford (European Pharmaceutical Review)Four new medicines were recommended for approval at the Committee for Medicinal Products for Human Use (CHMP)’s January meeting, with positive opinions given to two type 2 diabetes drugs.
articleEMA’s transformative treatments of 202024 February 2021 | By Hannah Balfour (European Pharmaceutical Review)In this article, we summarise the trial findings for the European Medicines Agency’s 13 most transformative therapies of 2020.
newsMerck to acquire VelosBio for $2.75 billion10 November 2020 | By Hannah Balfour (European Pharmaceutical Review)The acquisition will strengthen Merck’s oncology pipeline with VLS-101, an investigational antibody-drug conjugate in trials for haematological malignancies and solid tumours.
newsEC approves KTE-X19 for treatment of mantle cell lymphoma30 January 2020 | By Joe Doherty (European Pharmaceutical Review)KTE-X19, an investigational CAR T-cell therapy, has been granted marketing authorisation by the European Commission.
newsFDA approves Calquence for adults with mantle cell lymphoma1 November 2017 | By Dr Zara Kassam (European Pharmaceutical Review)The FDA has granted accelerated approval to Calquence for the treatment of adults with mantle cell lymphoma...
newsFDA grants Breakthrough Therapy Designation status for acalabrutinib1 August 2017 | By European Pharmaceutical ReviewIt has been announced that the FDA has awarded AstraZeneca’s acalabrutinib product for MCL treatment Breakthrough Therapy Designation...
newsEC approves Revlimid for mantle cell lymphoma15 July 2016 | By Victoria White, Digital Content ProducerCelgene’s Revlimid (lenalidomide) has been approved by the EC for the treatment of adult patients with relapsed or refractory mantle cell lymphoma...
newsJanssen’s IMBRUVICA® receives recommendation to broaden treatment application for CLL patients3 May 2016 | By Mandy Parrett, Editorial AssistantJanssen-Cilag International NV have reported that their therapy IMBRUVICA® (ibrutinib) has received a ‘Positive Opinion’ from the CHMP recommending that its use be extended for CLL patients.
newsNew follow-up data for IMBRUVICA® (ibrutinib) presented at ASH show longer term efficacy in patients with chronic lymphocytic Leukaemia and mantle cell lymphoma10 December 2014 | By JanssenJanssen-Cilag International NV (Janssen) is pleased to announce the presentation of new longer term follow-up data from two IMBRUVICA® (ibrutinib) studies at the American Society of Hematology (ASH) meeting in San Francisco, CA. IMBRUVICA is a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor.
newsEuropean Commission approves IMBRUVICA in two forms of blood cancer20 October 2014 | By JanssenJanssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor.
![Close up view of the Merck logo on the top corner of a glass building [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Merck-aquisition-300x278.jpg)
![Close up view of the Merck logo on the top corner of a glass building [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Merck-aquisition-scaled-e1605009301887.jpg)
